CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.
For the treatment of chronic hepatitis B virus infections
|
|
-->
-->
CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.
|
|
CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.
EVOMELA® (melphalan) for Injection, ZEVALIN® (ibritumomab tiuxetan), and MARQIBO® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.
© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.
